Cidara Therapeutics (CDTX) Misses Q2 EPS by 2051c

Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($20.65), $20.51 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $6.95 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• SpaceX Discusses Buying Data For Ai Models From Failed Startups - Bloomberg
• Roundtable signs $1B, 10-year deal with Paradium.AI for media platform